• About Us
    • Our Company
    • Management & Board
  • Aceragen
  • Tilsotolimod
    • Toll-Like Receptor Activation
    • Publications & Presentations
  • Investor Relations
×

Translational evidence of reactivated innate and adaptive immunity with intratumoral IMO-2125 in combination with systemic checkpoint inhibitors from a Phase 1/2 study in patients with anti-PD-1 refractory metastatic melanoma

© 2022 Idera. All rights reserved.

  • Contact Us
  • Terms of Use
  • Privacy Policy